Skip to main content

Maui Derm Hawaii, 2026

Filter
Close
Content type:
Bimekizumab Remission and High Disease Control Over 4 years in Patients with Psoriasis Achieving Complete Skin Clearance at Week 16: Results from Four Phase 3 Trials
Richard B. Warren, Bruce Strober, Denis Jullien, et al.
Poster
Bimekizumab Safety in Patients with Psoriasis Achieving Complete Skin Clearance: 4-year Analysis from 5 Phase 3/3b Trials
Diamant Thaçi, Kenneth B. Gordon, Richard G. Langley, et al.
Poster
Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT
John R. Ingram, Alexa B. Kimball, Amit Garg, et al.
Poster
Bimekizumab Improves HSSQ Skin Pain over 3 Years in HS: Data from BE HEARD EXT
Hadar Lev-Tov, Lauren A.V. Orenstein, Vivian Y. Shi, et al.
Poster